Ampio's Eye Drug Trial Design Won't Pass FDA Muster

"phase III" clinical trial of the low-dose steroid Optina in diabetic macular edema finally showed on the ClinicalTrials.gov registry maintained by the U.S. Food and Drug Administration, one month after the company announced treatment of the first patient.

http://www.thestreet.com/story/11884765/1/ampios-eye-drug-trial-design-wont-pass-fda-muster.html?cm_ven=RSSFeed